eFFECTOR Therapeutics Inc
NASDAQ:EFTR
Products, Regulatory
Effector Therapeutics Reports Positive Interim Results In Zotatifin Phase 1/2 Clinical Trial
Published: 06/05/2022 21:06 GMT
eFFECTOR Therapeutics Inc (EFTR) - Positive Interim Results in Zotatifin (eft226) Phase 1/2 Clinical Trial Showing Safety and Tolerability,.
Two Partial Responses Observed in Heavily Pre-treated Er+ Breast Cancer Patients.
Effector Therapeutics - Treatment Emergent Adverse Events (teaes) Related to Zotatifin Were Mostly Mild, Readily Managed and Reversible.
Anticipate Reporting Topline Data From Our Current Expansion Cohorts by End of 2022.
Two Partial Responses Observed in Heavily Pre-treated Er+ Breast Cancer Patients.
Effector Therapeutics - Treatment Emergent Adverse Events (teaes) Related to Zotatifin Were Mostly Mild, Readily Managed and Reversible.
Anticipate Reporting Topline Data From Our Current Expansion Cohorts by End of 2022.